Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Am J Obstet Gynecol. 2019 Nov 6;222(5):478.e1–478.e17. doi: 10.1016/j.ajog.2019.10.103

Figure 1.

Figure 1

Adjusted cross-sectional association between body mass index and the risk of vasomotor symptoms at baseline, stratified by menopausal status at baseline (premenopause: n=4,169; perimenopause: n=5,881; postmenopause: n=4,109). Relative risk ratio (RRR) and their 95% confidence intervals (95% CI) were adjusted for use of menopausal hormone therapy, race/ethnicity/region, education, and smoking status at baseline.